GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oramed Pharmaceuticals Inc (STU:OJU1) » Definitions » Debt-to-Equity

Oramed Pharmaceuticals (STU:OJU1) Debt-to-Equity : 0.00 (As of Sep. 2024)


View and export this data going back to 2007. Start your Free Trial

What is Oramed Pharmaceuticals Debt-to-Equity?

Oramed Pharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was €0.22 Mil. Oramed Pharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was €0.17 Mil. Oramed Pharmaceuticals's Total Stockholders Equity for the quarter that ended in Sep. 2024 was €140.95 Mil. Oramed Pharmaceuticals's debt to equity for the quarter that ended in Sep. 2024 was 0.00.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Oramed Pharmaceuticals's Debt-to-Equity or its related term are showing as below:

During the past 13 years, the highest Debt-to-Equity Ratio of Oramed Pharmaceuticals was 0.51. The lowest was 0.00. And the median was 0.01.

STU:OJU1's Debt-to-Equity is not ranked *
in the Biotechnology industry.
Industry Median: 0.14
* Ranked among companies with meaningful Debt-to-Equity only.

Oramed Pharmaceuticals Debt-to-Equity Historical Data

The historical data trend for Oramed Pharmaceuticals's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oramed Pharmaceuticals Debt-to-Equity Chart

Oramed Pharmaceuticals Annual Data
Trend Aug14 Aug15 Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Dec22 Dec23
Debt-to-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 0.01 0.01 0.32

Oramed Pharmaceuticals Quarterly Data
Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.51 0.32 0.20 - -

Competitive Comparison of Oramed Pharmaceuticals's Debt-to-Equity

For the Biotechnology subindustry, Oramed Pharmaceuticals's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Oramed Pharmaceuticals's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oramed Pharmaceuticals's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Oramed Pharmaceuticals's Debt-to-Equity falls into.



Oramed Pharmaceuticals Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Oramed Pharmaceuticals's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Oramed Pharmaceuticals's Debt to Equity Ratio for the quarter that ended in Sep. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Oramed Pharmaceuticals  (STU:OJU1) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.


Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.


Oramed Pharmaceuticals Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Oramed Pharmaceuticals's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Oramed Pharmaceuticals Business Description

Traded in Other Exchanges
Address
1185 Avenue of the Americas, Third Floor, New York, NY, USA, 10036
Oramed Pharmaceuticals Inc is a pharmaceutical company that is engaged in the research and development of pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. developed an oral dosage form intended to withstand the harsh environment of the stomach and effectively deliver active biological insulin or other proteins. Its product pipeline includes ORMD-0801, ORMD-0801, and ORMD 0901.

Oramed Pharmaceuticals Headlines

No Headlines